SG
KRBP

StoneX Group’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

StoneX Group’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$4.35K – 778
2022
Q3 		$4.35K Buy
+500
New +$5.8K ﹤0.01% 516

Other funds holding KRBP

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

StoneX Group's KRBP Position: Q4 2022 in Review

StoneX Group sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2022, closing a stake of 500 shares — an estimated $4.35K sold.

StoneX Group first reported a position in KRBP in Q3 2022 and held it in 1 quarter. The position peaked at $4.35K in Q3 2022. 12 funds tracked by Wall St. Rank hold KRBP as of Q4 2022.

  • StoneX Group reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • StoneX Group sold 500 Kiromic BioPharma, Inc. Common Stock shares in Q4 2022, an estimated $4.35K.
  • StoneX Group first reported a position in Kiromic BioPharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • StoneX Group's Kiromic BioPharma, Inc. Common Stock position peaked at $4.35K in Q3 2022.
  • 12 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.